Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells.
Level 5 - mechanism / opinion, no new human data
In vitro laboratory study using isolated canine mast cells
PubMed 19625089 · doi:10.1016/j.vetimm.2009.06.011
What was done
Canine mast cells freshly isolated from skin biopsies were sensitized with IgE-rich serum and challenged with anti-canine IgE. The release of histamine, prostaglandin D2 (PGD2), and tumour necrosis factor-alpha (TNFalpha) was measured in the presence and absence of increasing concentrations of palmitoylethanolamide (PEA) ranging from 10(-8)M to 10(-5)M.
What was found
PEA significantly inhibited the release of all three mediators. Maximum inhibition of histamine release reached 54.3+/-5.2% at 3x10(-6)M PEA. PGD2 release was inhibited by 25.5+/-10.2% at 10(-5)M and 14.6+/-5.6% at 10(-6)M PEA. TNFalpha release was inhibited by 29.2+/-2.0% at 10(-5)M and 22.1+/-7.2% at 3x10(-6)M PEA.
Why it matters
This study provides mechanistic evidence that PEA directly down-modulates canine skin mast cell degranulation, helping explain its reported anti-inflammatory efficacy in canine skin disease.
Limits
The study was conducted entirely in vitro on isolated cells and does not reflect in vivo pharmacokinetics, tissue penetration, or clinical outcomes. The abstract does not report the number of dog donors (sample size) or experimental replicates.
Cited by
- supports Palmitoylethanolamide (PEA) helps with histamine issues.